Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,140 | 8-10 weeks | |
50 mg | $2,785 | 8-10 weeks | |
100 mg | $3,520 | 8-10 weeks |
Description | CXCR4 antagonist 7 (Compound PARA-B) is able to be used in the HIV infection, inflammatory diseases, cancer, and WHIM syndrome research which is a antagonist of CXCR4 (IC 50 = 9.3 nM) [1]. |
In vitro | CXCR4 antagonist 7 (PARA-B, ranging from 10 nM to 1 μM, over various periods) demonstrates multiple inhibitory effects on GH4C1 cell activities. Specifically, at concentrations between 10 nM and 1 μM over 20 hours, it suppresses CXCL12-stimulated GH4C1 proliferation with an IC50 of 9.3 nM. When applied at 1 μM for 12 hours, it halts CXCL12-dependent GH4C1 migration by 50%. Additionally, at 50 nM for 30 minutes, it decreases ERK1/2 phosphorylation prompted by CXCL12. This antagonist operates through CXCR4 inhibition to counteract CXCL12-triggered GH4C1 proliferation and migration. Testing at 1 μM for 24 hours in a cell viability assay indicates no detrimental effect on GH4C1 cell survival. Further analysis shows it impedes the proliferation of various cancer cells (10 nM-1 μM for 20 to 24 hours) with IC50 values between 1.08 and 3.45 μM, without affecting GH4C1 cell viability. In migration assays (50 nM-1 μM, 12 hours for GH4C1 and 30 minutes for GH4A11), it significantly reduces GH4C1 migration, though no impact is observed on GH4A11 cells, even with CRISPR-Cas9-induced CXCR4 mRNA reduction. Western blot analysis reinforces these findings, demonstrating a reduction in CXCL12-induced ERK1/2 phosphorylation at 50 nM over 30 minutes. |
Molecular Weight | 315.33 |
Formula | C15H17N5O3 |
Cas No. | 1185451-72-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.